Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | PPIA | P62937 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5110550 | 0.94 | GHSR (0.33) | GHSRMEN1MAPK1KMT2ADGAT1 | |
| SCHEMBL2051406 | 0.94 | GHSR (0.33) | GHSRMEN1MAPK1KMT2ADGAT1 | |
| SCHEMBL26233734 | 0.91 | MEN1 (0.34) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL28778018 | 0.86 | PPIA (0.32) | GHSRPPIA | |
| SCHEMBL29861514 | 0.86 | GAA (0.35) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL21506242 | 0.86 | GHSR (0.31) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL31730642 | 0.85 | GHSR (0.32) | GHSRMEN1MAPK1KMT2A | |
| SCHEMBL22766211 | 0.85 | MEN1 (0.36) | GHSRMEN1MAPK1KMT2ADGAT1 | |
| SCHEMBL21506348 | 0.82 | GHSR (0.30) | GHSR | |
| SCHEMBL16462945 | 0.81 | GHSR (0.50) | GHSRCTSLPPIAJAK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371400-B2 | Cathepsin inhibitors | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-07-29 | — | — | US | disclosed |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2024-09-12 | — | — | US | disclosed |
| US-20240182409-A1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2024-06-06 | — | — | US | disclosed |
| EP-4352049-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | Avelos Therapeutics Inc. (KR) | 2024-04-17 | — | — | EP | disclosed |
| US-11820734-B2 | Cathepsin inhibitors | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2023-11-21 | — | — | US | disclosed |
| WO-2022260441-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVELOS THERAPEUTICS INC. (KR) | 2022-12-15 | — | — | WO | disclosed |
| US-20220227705-A1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2022-07-21 | — | — | US | disclosed |
| EP-3720840-B1 | CATHEPSIN INHIBITORS | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2022-01-19 | — | — | EP | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| US-11174224-B2 | Cathepsin inhibitors | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2021-11-16 | — | — | US | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| US-7488848-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| EP-1865940-A2 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Applera Corporation (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1866276-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORPORATION (US) | 2007-01-25 | — | — | US | disclosed |
| WO-2006102243-A2 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | APPLERA CORPORATION (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102423-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | GHSR 322/4885MEN1 4563/4885MAPK1 958/4885 |
| US-11820734-B2 | Cathepsin inhibitors | CTSK, CTSZ, CTSF | GHSR 3175/4885MEN1 4333/4885MAPK1 3538/4885 |
| US-12371400-B2 | Cathepsin inhibitors | CTSK, CTSZ, CTSF | GHSR 3175/4885MEN1 4333/4885MAPK1 3538/4885 |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | CTSS, CTSF, CTSB | GHSR 3220/4885MEN1 4435/4885MAPK1 3833/4885 |
| US-20240300936-A1 | PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS | MAST1, MAST3, MAST4 | GHSR 4179/4885MEN1 966/4885MAPK1 125/4885 |
| US-11174224-B2 | Cathepsin inhibitors | CTSK, CTSZ, CTSF | GHSR 3175/4885MEN1 4333/4885MAPK1 3538/4885 |
| US-20220227705-A1 | CATHEPSIN INHIBITORS | CTSK, CTSZ, CTSF | GHSR 3175/4885MEN1 4333/4885MAPK1 3538/4885 |
| US-20240182409-A1 | CATHEPSIN INHIBITORS | CTSK, CTSZ, CTSF | GHSR 3175/4885MEN1 4333/4885MAPK1 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.